Related Experiment Videos
Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis
1Bristol Heart Institute, Level 7, Bristol Royal Infirmary, Upper Maudlin Street, Bristol, BS2 8HW, UK. s.j.george@bris.ac.uk
Abstract:
The activity of matrix-degrading metalloproteinases (MMPs) is essential for many of the processes involved in atherosclerotic plaque formation, for example, infiltration of inflammatory cells, smooth muscle cell migration and proliferation and angiogenesis. Furthermore, matrix degradation by MMPs may cause the plaque instability and rupture that leads to the clinical symptoms of atherosclerosis; unstable angina, myocardial infarction and stroke. Together, the family of MMPs can degrade all of the components of the blood vessel extracellular matrix and their activity therefore, is tightly regulated in normal blood vessels. The increased MMP activity during atherosclerotic plaque development and instability must therefore be caused by increased cytokine and growth factor-stimulated gene transcription, elevated zymogen activation and an imbalance in the MMP:TIMP ratio. It is therefore conceivable that inhibition of MMPs or re-establishing the MMP:TIMP balance may be useful in treating the symptoms of atherosclerosis. Recent studies using synthetic MMP inhibitors and gene therapy have highlighted the potential of such an approach.
Insights
Matrix-degrading metalloproteinases (MMPs) drive atherosclerosis development and plaque rupture. Inhibiting MMPs or restoring MMP:TIMP balance may treat cardiovascular diseases like heart attack and stroke.
Area of Science:
- Cardiovascular Biology
- Extracellular Matrix Remodeling
- Enzyme Function in Disease
Background:
- Matrix-degrading metalloproteinases (MMPs) are crucial for atherosclerotic plaque development, including inflammatory cell infiltration, smooth muscle cell migration, and angiogenesis.
- MMP activity contributes to plaque instability and rupture, leading to clinical events such as myocardial infarction and stroke.
- MMPs degrade extracellular matrix components, and their activity is tightly regulated in healthy vessels but dysregulated in atherosclerosis.
Purpose of the Study:
- To investigate the role of MMPs in the pathogenesis of atherosclerosis.
- To explore the potential of MMP inhibition or restoring MMP:TIMP balance as a therapeutic strategy for atherosclerosis.
Main Methods:
- Review of existing literature on MMP activity in atherosclerosis.
- Analysis of mechanisms leading to increased MMP activity during plaque development.
- Evaluation of recent studies on synthetic MMP inhibitors and gene therapy.
Main Results:
- Increased MMP activity, driven by cytokine/growth factor signaling, zymogen activation, and MMP:TIMP imbalance, promotes atherosclerotic plaque progression and instability.
- Degradation of the extracellular matrix by MMPs is a key factor in plaque rupture and subsequent clinical events.
- Synthetic MMP inhibitors and gene therapy show promise in preclinical studies.
Conclusions:
- Targeting MMPs or re-establishing the MMP:TIMP balance represents a potential therapeutic avenue for managing atherosclerosis and its complications.
- Further research into MMP inhibition strategies is warranted for the treatment of cardiovascular diseases.